DE2601915A1 - Verfahren zur herstellung von beta- peltatin-a-o-alpha-l-arabinofuranosids - Google Patents
Verfahren zur herstellung von beta- peltatin-a-o-alpha-l-arabinofuranosidsInfo
- Publication number
- DE2601915A1 DE2601915A1 DE19762601915 DE2601915A DE2601915A1 DE 2601915 A1 DE2601915 A1 DE 2601915A1 DE 19762601915 DE19762601915 DE 19762601915 DE 2601915 A DE2601915 A DE 2601915A DE 2601915 A1 DE2601915 A1 DE 2601915A1
- Authority
- DE
- Germany
- Prior art keywords
- peltatin
- arabinofuranosids
- preparation
- formula
- moles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims description 6
- 238000002360 preparation method Methods 0.000 title claims description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 18
- HLBPOYVRLSXWJJ-UHFFFAOYSA-N beta-Peltatin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C(O)=C3CC3C2C(OC3)=O)=C1 HLBPOYVRLSXWJJ-UHFFFAOYSA-N 0.000 claims description 10
- HLBPOYVRLSXWJJ-PDSMFRHLSA-N beta-peltatin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C(O)=C3C[C@@H]3[C@@H]2C(OC3)=O)=C1 HLBPOYVRLSXWJJ-PDSMFRHLSA-N 0.000 claims description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 9
- 229940057499 anhydrous zinc acetate Drugs 0.000 claims description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 3
- FQGYCXFLEQVDJQ-UHFFFAOYSA-N mercury dicyanide Chemical compound N#C[Hg]C#N FQGYCXFLEQVDJQ-UHFFFAOYSA-N 0.000 claims description 3
- DJWUNCQRNNEAKC-UHFFFAOYSA-L zinc acetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O DJWUNCQRNNEAKC-UHFFFAOYSA-L 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 12
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000011278 mitosis Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- -1 tri-O Chemical class 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- 241000228245 Aspergillus niger Species 0.000 description 1
- 102000005575 Cellulases Human genes 0.000 description 1
- 108010084185 Cellulases Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 description 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Substances CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- OAABHEHWRQAHEJ-UHFFFAOYSA-N butan-1-ol;chloroform Chemical compound ClC(Cl)Cl.CCCCO OAABHEHWRQAHEJ-UHFFFAOYSA-N 0.000 description 1
- 230000003327 cancerostatic effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- OAIVIYSBZFEOIU-UHFFFAOYSA-N chloroform;propan-2-one Chemical compound CC(C)=O.ClC(Cl)Cl OAIVIYSBZFEOIU-UHFFFAOYSA-N 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- BQPIGGFYSBELGY-UHFFFAOYSA-N mercury(2+) Chemical compound [Hg+2] BQPIGGFYSBELGY-UHFFFAOYSA-N 0.000 description 1
- 150000002825 nitriles Chemical group 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 229960000314 zinc acetate Drugs 0.000 description 1
- 239000004246 zinc acetate Substances 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DD18540875A DD118876A1 (enExample) | 1975-04-14 | 1975-04-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2601915A1 true DE2601915A1 (de) | 1976-10-28 |
Family
ID=5499918
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19762601915 Pending DE2601915A1 (de) | 1975-04-14 | 1976-01-20 | Verfahren zur herstellung von beta- peltatin-a-o-alpha-l-arabinofuranosids |
Country Status (5)
| Country | Link |
|---|---|
| CH (1) | CH599241A5 (enExample) |
| DD (1) | DD118876A1 (enExample) |
| DE (1) | DE2601915A1 (enExample) |
| FR (1) | FR2307821A1 (enExample) |
| GB (1) | GB1491639A (enExample) |
-
1975
- 1975-04-14 DD DD18540875A patent/DD118876A1/xx unknown
-
1976
- 1976-01-20 DE DE19762601915 patent/DE2601915A1/de active Pending
- 1976-03-18 GB GB1090976A patent/GB1491639A/en not_active Expired
- 1976-04-12 CH CH463276A patent/CH599241A5/xx not_active IP Right Cessation
- 1976-04-14 FR FR7611044A patent/FR2307821A1/fr not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| FR2307821A1 (fr) | 1976-11-12 |
| DD118876A1 (enExample) | 1976-03-20 |
| GB1491639A (en) | 1977-11-09 |
| CH599241A5 (enExample) | 1978-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CH666039A5 (de) | Isomere 0-phosphonylmethylderivate enantiomerer und racemischer vicinaler diole und verfahren zu ihrer herstellung. | |
| DE2718038C2 (de) | Verfahren zur Razemisierung eines Esters einer optisch aktiven Cyclopropancarbonsäure mit einem optisch aktiven &alpha;-Cyan-3-phenoxybenzylalkohol zu einem Ester einer optisch aktiven Säure mit dem racemischen &alpha;-Cyan-3-phenoxybenzylalkohol | |
| DD141833A5 (de) | Verfahren zur herstellung von o-substituierten derivaten des(+)-cyanidan-3-ols | |
| DE1910481A1 (de) | Neue 3,3,5-Trimethylcyclohexylester und Verfahren zu ihrer Herstellung | |
| DE2601915A1 (de) | Verfahren zur herstellung von beta- peltatin-a-o-alpha-l-arabinofuranosids | |
| EP0413700A1 (de) | Neue alkylphosphono- und phosphoserine, verfahren zu deren herstellung und diese enthaltende pharmazeutische mittel | |
| DE2322893A1 (de) | Prostaglandin e tief 1 -vorprodukte und verfahren zu ihrer herstellung | |
| DE2817923C2 (de) | Septacidinverbindungen und diese enthaltende Arzneimittel | |
| DE2616351A1 (de) | Halogenderivate | |
| DE2948116A1 (de) | Verfahren zur herstellung von apovincaminsaeureester-derivaten | |
| CH621544A5 (enExample) | ||
| DE2014277B2 (de) | Verfahren zur Herstellung von Acylderivaten des Antibiotikums T-2636 C | |
| DD240020A1 (de) | Verfahren zur herstellung neuer, pharmakologisch hochwirksamer phospholipide | |
| DE69610213T2 (de) | Verfahren zur herstellung bestimmter acetonitrilen | |
| EP0181409B1 (de) | 15(r+s)-fluor-11,15-didesoxyprostaglandin-e1-abkömmlinge | |
| DE2335764A1 (de) | Theophyllinderivate und verfahren zu deren herstellung | |
| DE1801312A1 (de) | Verfahren zur Herstellung einer neuen Aryloxyalkansaeure und ihrer Salze | |
| DE2303612C3 (de) | Verfahren zur Herstellung von Prostaglandinen | |
| DE2016704C3 (de) | Ein neues, herzwirksames 14,15 ß -Oxidobufadienolid-LRhamnosid und Verfahren zu seiner Herstellung | |
| DE2435617C3 (de) | L-Asparaginsäuresalz des cyklischen Erythromycin A-carbonats sowie ein Verfahren zur Herstellung desselben und pharmazeutische Mittel mit einem Gehalt dieser Verbindung | |
| AT222807B (de) | Verfahren zur Herstellung eines therapeutisch wirksamen Produktes | |
| DE1620559C3 (de) | Verfahren zur Herstellung von Gemischen aus N-Alkyl-isoajmaliniumsalzen und N-Alkyl-ajmaliniumsalzen | |
| DE2209391B2 (de) | Verfahren zur Herstellung der 3-0-(beta-carboxypropionyty-lS-beta-Glycyrrhetinsäure | |
| DE2240427C3 (de) | Cyclohexylthiophosphorsäureester, Verfahren zu Ihrer Herstellung und ihre Verwendung | |
| DE2365322C3 (de) | Subst.-Methyl-phosphonsäuredimethylester und ein Verfahren zu ihrer Herstellung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OHJ | Non-payment of the annual fee |